View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.


PER Pulse™ Recaps highlight key elements in the Community Practice Connections™: 2nd Annual School of Gastrointestinal Oncology™ online CME activity

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Celgene Corporation, Lilly, Merck Sharp & Dohme Corp., Sirtex Medical Inc., and Taiho Oncology.

For further information concerning Lilly grant funding, visit

Community Practice Connections™: 2nd Annual School of Gastrointestinal Oncology™

Release Date: June 30, 2017
Expiration Date: June 30, 2018
Media: Internet - based


Activity Overview

Community Practice Connections™: 2nd Annual School of Gastrointestinal Oncology (SOGO™) is a continuing medical education (CME)-certified activity based on a symposium of the same name held in New York, NY, on April 29, 2017.

SOGO™ has been developed as a dynamic and interactive, curriculum-based program covering the most important concepts related to the multidisciplinary management of gastrointestinal (GI) cancers. This 3-track program—medical; surgical and radiation; and multidisciplinary management and communication—allowed participants to customize their educational experience, while bringing together all attendees for several multidisciplinary plenary sessions.

This CME activity consists of a series of brief interviews with 3 noted SOGO™ faculty members exploring clinically relevant questions from the community physician perspective. Important topics addressed in this activity include:

  • Impact of microsatellite instability (MSI) status on prognosis of GI cancers
  • How MSI should be measured
  • Evolving role of immunotherapy in hepatocellular carcinoma (HCC) and other GI cancers
  • What is a plasma (ie, liquid) biopsy, and how can it be used?
  • Use of broad molecular profiling, now and in the future
  • Recent approval of regorafenib for HCC

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, surgeons, and radiologists involved in the treatment of GI cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals involved in the treatment of GI cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Explain prognostic and predictive markers, and how they can be used to stratify risk and inform clinical decision making in the management of gastrointestinal (GI) malignancies
  2. Apply pivotal trial evidence in the personalized management of advanced forms of GI tumors
  3. Outline multidisciplinary methods to proactively plan for, prevent, and mitigate treatment-related toxicities
  4. Detail the most clinically relevant clinical trial findings concerning emerging strategies to manage GI malignancies
  5. Apply emerging clinical trial data to manage cases in the context of evolving treatment paradigms for GI tumors

Faculty, Staff, and Planners' Disclosures


John L. Marshall, MD
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
Washington, DC

Disclosure: Grant/Research Support: Genentech, Amgen, Bayer, Celgene, Taiho Oncology, Caris Life Sciences; Consultant: Genentech, Amgen, Celgene, Bayer, Indivumed, Caris Life Sciences; Speakers Bureau: Genentech, Amgen, Bayer, Celgene, Taiho Oncology


Cathy Eng, MD, FACP
Director and Professor
Department of Gastrointestinal Medical Oncology
Network Clinical Research
Associate Medical Director, Colorectal Center
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/Research Support: Daiichi-Sankyo, Keryx Biopharmaceuticals; Consultant: Bayer; Speakers Bureau: Genentech

Aiwu Ruth He, MD, PhD
Associate Professor of Medicine
Division of Hematology/Oncology
Georgetown University School of Medicine
Washington, DC

Disclosure: Grant/Research Support: Merck Sharp & Dohme, EMD Serono; Consultant: Bayer, Bristol-Myers Squibb; Advisory Board: Bayer, Bristol-Myers Squibb, Merck Sharp & Dohme

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By